Clinical trial
A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects
NCT05938946 is registered in ClinicalTrials.gov with Pharmosa Biopharm Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects
- Lead sponsor
- Pharmosa Biopharm Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 30, 2023
- Completion date
- September 2, 2024
- Enrollment
- 64 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.